Although activation of MET and JNK is not reported to be associated with BCR-ABL1-independent imatinib resistance in CML patients, there are indications that ABL1 interacts with oncogenic MET [30]. Here, MET is linked to chronic myelogenous leukemia, BCR-ABL1 positive.